Market Overview:
The global pulmonary arterial hypertension (PAH) medicine market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of PAH, rising awareness about PAH, and technological advancements in the field of PAH treatment. The global pulmonary arterial hypertension (PAH) medicine market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into endothelin receptor antagonists (ERA), prostacyclin and prostacyclin analogs, phosphodiesterase 5 inhibitors (PDE-5), and soluble guanylate cyclase stimulators. On the basis of application, the market is divided into secondary pulmonary hypertension (SPH) and primary pulmonary hypertension (PPH). Geographically, it is analyzed across North America, Latin America,, Europe,, Asia Pacific,,and Middle East & Africa . Some key players operating in this market are Actelion Pharmaceuticals Ltd., Bayer AG., Gilead Sciences Inc., GlaxoSmithKline plc., Novartis AG., Pfizer Inc.
 Medicine Industry Outlook.svg)
Product Definition:
Pulmonary arterial hypertension is a type of high blood pressure that affects the arteries in your lungs. It can cause shortness of breath, tiredness, and chest pain. Pulmonary arterial hypertension is a rare condition that affects about 200,000 people in the United States.
Endothelin Receptor Antagonists (ERA):
Endothelin receptor antagonists (ERA) is a class of drugs that blocks the activity of endothelin-1, an endothelium-derived hyperthrombogenic factor. Endothelins are a group of small peptides with vasoconstrictor and hypertensive properties. By inhibiting the action of endothelial derived endothelin, these drugs reduce blood pressure in patients suffering from PAH.
Prostacyclin And Prostacyclin Analogs:
Prostacyclin and prostacyclin analogs are types of pulmonary vasodilators. Prostacyclin is a type of short-acting cyclic peptide antibiotics that inhibits the release of endotoxin by immune cells. It has wide applications in the treatment of conditions such as bronchitis, pneumonia, and inflammation associated with chronic respiratory diseases such as asthma and PAH.
Application Insights:
The primary application segment of the global market is secondary pulmonary hypertension (SPH). The others application segment includes primary pulmonary hypertension (PPH) and other rare diseases. In 2017, secondary pulmonary hypertension was dominant in terms of revenue as well as in terms of volume. This is due to a high prevalence rate and increasing awareness about the disease among patients suffering from PPH.
In 2015, according to data published by WHO, around 5% - 10% of people across the globe are affected with PAH which indicates a huge unmet medical need for effective treatment options for this disease. Therefore, there is an immense potential market waiting to be tapped if proper diagnosis and treatment procedures are available globally.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high awareness levels, and availability of advanced treatment options for Pulmonary Arterial Hypertension (PAH). In addition, increasing prevalence of chronic diseases such as diabetes and obesity is also expected to boost growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising healthcare expenditure by governments along with an increase in demand for quality medicines that are effective & efficient. Moreover, growing medical tourism industry due to low cost treatment & diagnosis will also drive regional market growth during the forecast period.
Growth Factors:
- Increasing prevalence of PAH due to various risk factors such as obesity, smoking, and genetics is expected to drive the growth of the pulmonary arterial hypertension (PAH) medicine market.
- Rising awareness about PAH and its symptoms is anticipated to fuel the demand for PAH medicines in the near future.
- Technological advancements in PAH treatment therapies are likely to boost the growth of this market during the forecast period.
- Growing number of clinical studies on new drugs for treating PAH is projected to create lucrative opportunities for players operating in this market over the next few years.
- increasing healthcare expenditure by governments and private players is expected to propel demand for better healthcare facilities including diagnosis and treatment of Pulmonary Arterial Hypertension (PAH) Medicine across different geographies
Scope Of The Report
Report Attributes
Report Details
Report Title
Pulmonary Arterial Hypertension (PAH) Medicine Market Research Report
By Type
Endothelin Receptor Antagonists (ERA), Prostacyclin And Prostacyclin Analogs, Phosphodiesterase 5 (PDE-5), Soluble Guanylate Cyclase (SGC) Stimulators
By Application
Secondary Pulmonary Hypertension (SPH), Primary Pulmonary Hypertension (PPH)
By Companies
Actelion Pharmaceuticals, Gilead Sciences, United Therapeutics Corporation, GlaxoSmithKline, Pfizer, Bayer HealthCare, Arena Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Pulmonary Arterial Hypertension (PAH) Medicine Market Report Segments:
The global Pulmonary Arterial Hypertension (PAH) Medicine market is segmented on the basis of:
Types
Endothelin Receptor Antagonists (ERA), Prostacyclin And Prostacyclin Analogs, Phosphodiesterase 5 (PDE-5), Soluble Guanylate Cyclase (SGC) Stimulators
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Secondary Pulmonary Hypertension (SPH), Primary Pulmonary Hypertension (PPH)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Actelion Pharmaceuticals
- Gilead Sciences
- United Therapeutics Corporation
- GlaxoSmithKline
- Pfizer
- Bayer HealthCare
- Arena Pharmaceuticals
 Medicine Market Overview.svg)
Highlights of The Pulmonary Arterial Hypertension (PAH) Medicine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Endothelin Receptor Antagonists (ERA)
- Prostacyclin And Prostacyclin Analogs
- Phosphodiesterase 5 (PDE-5)
- Soluble Guanylate Cyclase (SGC) Stimulators
- By Application:
- Secondary Pulmonary Hypertension (SPH)
- Primary Pulmonary Hypertension (PPH)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pulmonary Arterial Hypertension (PAH) Medicine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Medicine Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pulmonary arterial hypertension (PAH) is a medical condition in which the arteries that supply blood to the lungs become enlarged and unable to function properly. This can lead to shortness of breath, chest pain, and even death. PAH is most commonly caused by smoking, but can also be caused by other factors such as high blood pressure or obesity. Treatment for PAH typically includes medications and surgery.
Some of the major companies in the pulmonary arterial hypertension (pah) medicine market are Actelion Pharmaceuticals, Gilead Sciences, United Therapeutics Corporation, GlaxoSmithKline, Pfizer, Bayer HealthCare, Arena Pharmaceuticals.
The pulmonary arterial hypertension (pah) medicine market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pulmonary Arterial Hypertension (PAH) Medicine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pulmonary Arterial Hypertension (PAH) Medicine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pulmonary Arterial Hypertension (PAH) Medicine Market - Supply Chain
4.5. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Forecast
4.5.1. Pulmonary Arterial Hypertension (PAH) Medicine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pulmonary Arterial Hypertension (PAH) Medicine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pulmonary Arterial Hypertension (PAH) Medicine Market Absolute $ Opportunity
5. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Volume Forecast by Type
5.3.1. Endothelin Receptor Antagonists (ERA)
5.3.2. Prostacyclin And Prostacyclin Analogs
5.3.3. Phosphodiesterase 5 (PDE-5)
5.3.4. Soluble Guanylate Cyclase (SGC) Stimulators
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Volume Forecast by Application
6.3.1. Secondary Pulmonary Hypertension (SPH)
6.3.2. Primary Pulmonary Hypertension (PPH)
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pulmonary Arterial Hypertension (PAH) Medicine Demand Share Forecast, 2019-2026
9. North America Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Volume Forecast by Application
9.4.1. Secondary Pulmonary Hypertension (SPH)
9.4.2. Primary Pulmonary Hypertension (PPH)
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Volume Forecast by Type
9.7.1. Endothelin Receptor Antagonists (ERA)
9.7.2. Prostacyclin And Prostacyclin Analogs
9.7.3. Phosphodiesterase 5 (PDE-5)
9.7.4. Soluble Guanylate Cyclase (SGC) Stimulators
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pulmonary Arterial Hypertension (PAH) Medicine Demand Share Forecast, 2019-2026
10. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Volume Forecast by Application
10.4.1. Secondary Pulmonary Hypertension (SPH)
10.4.2. Primary Pulmonary Hypertension (PPH)
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Volume Forecast by Type
10.7.1. Endothelin Receptor Antagonists (ERA)
10.7.2. Prostacyclin And Prostacyclin Analogs
10.7.3. Phosphodiesterase 5 (PDE-5)
10.7.4. Soluble Guanylate Cyclase (SGC) Stimulators
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Demand Share Forecast, 2019-2026
11. Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Volume Forecast by Application
11.4.1. Secondary Pulmonary Hypertension (SPH)
11.4.2. Primary Pulmonary Hypertension (PPH)
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Volume Forecast by Type
11.7.1. Endothelin Receptor Antagonists (ERA)
11.7.2. Prostacyclin And Prostacyclin Analogs
11.7.3. Phosphodiesterase 5 (PDE-5)
11.7.4. Soluble Guanylate Cyclase (SGC) Stimulators
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pulmonary Arterial Hypertension (PAH) Medicine Demand Share, 2019-2026
12. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Volume Forecast by Application
12.4.1. Secondary Pulmonary Hypertension (SPH)
12.4.2. Primary Pulmonary Hypertension (PPH)
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Volume Forecast by Type
12.7.1. Endothelin Receptor Antagonists (ERA)
12.7.2. Prostacyclin And Prostacyclin Analogs
12.7.3. Phosphodiesterase 5 (PDE-5)
12.7.4. Soluble Guanylate Cyclase (SGC) Stimulators
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Demand Share, 2019-2026
13. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Volume Forecast by Application
13.4.1. Secondary Pulmonary Hypertension (SPH)
13.4.2. Primary Pulmonary Hypertension (PPH)
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Volume Forecast by Type
13.7.1. Endothelin Receptor Antagonists (ERA)
13.7.2. Prostacyclin And Prostacyclin Analogs
13.7.3. Phosphodiesterase 5 (PDE-5)
13.7.4. Soluble Guanylate Cyclase (SGC) Stimulators
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Pulmonary Arterial Hypertension (PAH) Medicine Market: Market Share Analysis
14.2. Pulmonary Arterial Hypertension (PAH) Medicine Distributors and Customers
14.3. Pulmonary Arterial Hypertension (PAH) Medicine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Actelion Pharmaceuticals
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Gilead Sciences
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. United Therapeutics Corporation
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. GlaxoSmithKline
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Pfizer
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Bayer HealthCare
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Arena Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
